Last reviewed · How we verify
Estraimod Immediate Release (IR) (estraimod-immediate-release-ir)
At a glance
| Generic name | estraimod-immediate-release-ir |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Vessel puncture site haematoma
- Lip dry
- Puncture site erythema
- Atrioventricular block first degree
- Vision blurred
- Nausea
- Fatigue
- Post procedural haematoma
- Skin laceration
- Dysgeusia
- Headache
- Nasal congestion
Key clinical trials
- A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estraimod Immediate Release (IR) CI brief — competitive landscape report
- Estraimod Immediate Release (IR) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI